TITLE

No Metabolic Side Effects of Long--Term Treatment with Verapamil in Hypertension

AUTHOR(S)
Midtbø, Kjell; Lauve, Oddveig; Hals, Ottar
PUB. DATE
December 1988
SOURCE
Angiology;Dec1988, Vol. 39 Issue 12, p1025
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In a prospective, open study 45 patients (mean age fifty-three years) with essential hypertension were treated with verapamil for four to eight years (mean 5.3 years). Blood pressure was satisfactorily controlled (from 160/104 to 145/91) and the side effects were infrequent, mild, and often transient. Verapamil did not exert any unfavorable metabolic or hematologic effects over the years. HDL-cholesterol was moderately increased (mean 24%) and the other plasma lipids were unaffected. These data suggest that the calcium channel blocker verapamil is a metabolically safe drug to use as monotherapy in essential hypertension.
ACCESSION #
16347784

 

Related Articles

  • High Blood Pressure, the Heart--and Hope: Are Prevention and Cure Being Ignored Because of a Fascination with Control Drugs? Renaurd, William // Nutrition Health Review: The Consumer's Medical Journal;2006, Issue 96, p12 

    The article presents a reprint of the article "High Blood Pressure, the Heart-and Hope: Are Prevention and Cure Being Ignored Because of a Fascination With Control Drugs," which appeared in issue 16 of the periodical "Nutrition Health Review." According to the article, the most valuable defense...

  • Ouabain Antagonists as Antihypertensive Agents. Ferrandi, M.; Barassi, P.; Molinari, I.; Torielli, L.; Tripodi, G.; Minotti, E.; Bianchi, G.; Ferrari, P. // Current Pharmaceutical Design;Sep2005, Vol. 11 Issue 25, p3301 

    The evidence that high levels of endogenous ouabain (EO), a closely related isomer of ouabain, are implicated in human hypertension and cardiac hypertrophy and failure stimulated the pharmacological research for developing novel anti-hypertensive agents active as ouabain antagonists. The...

  • HYPERTENSION.  // Current Medical Literature: Cardiology;2005, Vol. 24 Issue 4, p84 

    The article presents the comments of clinicians on several studies about hypertension. These include "Major clinical trials of hypertension: What should be done next?" "Resistant hypertension," "Superiority of ambulatory over clinical blood pressure measurement in predicting mortality: the Dubin...

  • Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension. Augustyniak, Robert A.; Thomas, Gail D.; Victor, Ronald G.; Weiguo Zhang // Current Pharmaceutical Design;Sep2005, Vol. 11 Issue 25, p3307 

    Nitric oxide (NO) is thought to reduce blood pressure by evoking vasodilation either directly by causing relaxation of vascular smooth muscle or indirectly by acting in the rostral brainstem to reduce central sympathetic outflow, which decreases the release of norepinephrine from sympathetic...

  • Quinapril: A Double-Blind, Placebo-Controlled Trial in Essential Hypertension. Maclean, Derek // Angiology;Apr1989 Part 2, Vol. 40 Issue 4, p370 

    Quinapril HCl is a novel, nonsulfhydryl angiotensin-converting enzyme (ACE) inhibitor. The Study Group evaluated its efficacy (20, 40, 80 mg daily with forced dose titration determination at trough blood pressure) once daily versus twice daily versus placebo, as well as its tolerability and...

  • ACE Inhibition in Hypertension: Focus on Perindopril. Cockcroft, John R. // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 4, p303 

    Ongoing developments in our understanding of cardiovascular disease, together with the introduction of new drugs to treat these conditions, has led to much debate over the optimal management of hypertension. The ALLHAT study showed no major differences in cardiovascular outcome among three...

  • ALPHA METHYL DOPA IN HYPERTENSION. Datey, K. K.; Pandya, V. N. // Angiology;Apr1965, Vol. 16 Issue 4, p155 

    1. Alpha methyl dopa was tried on 39 hypertensive patients. 2. Methyldopa is a decarboxylase inhibitor. However, its exact mode of hypertensive action is not clear. 3. It acts in about 3 to 4 hr., and the duration of its action is about 6 to 8 hr. The maximal effect occurs 24 to 48 hr. after...

  • Drugs yield "surprising" BP control.  // Cortlandt Forum;7/25/2005, Vol. 18 Issue 7, p18 

    Reports that a combination of irbesartan and hydrochlorothiazide can reduce systolic blood pressure (SBP) in patients with mild-to-moderate hypertension. Percentage on the reduction in SBP after eighteen weeks of combined therapy; Dosage of the combined therapy administered to the patients;...

  • Secondary stroke prophylaxis: ARB bests calcium antagonist.  // Formulary;May2005, Vol. 40 Issue 5, p157 

    Discusses a study which suggested that the angiotensin receptor blocker (ARB) eprosartan is superior to the calcium antagonist nitrendipine in secondary stroke prophylaxis in patients with hypertension. Findings reported by Dr. Hans-Chrisdan Diener at the American Stroke Association's...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics